Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints
Retrieved on:
Thursday, September 12, 2019
Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
Key Points:
- Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
- The study demonstrated that maintenance treatment with CC-486 resulted in a highly statistically significant and clinically meaningful improvement in overall survival compared to placebo.
- The key secondary endpoint of relapse-free survival (RFS) also showed a statistically significant improvement.
- Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control.